Triclinium will for the third time participate in the annual VPM Days Conference in Hannover, Germany on 15th – 16th September 2016.
VPM is Vakzine Projekt Management, a public–private partnership venture founded jointly by the German Federal Ministry of Education and Research and the Braunschweig-based Helmholtz Centre for Infection Research in 2002. Since 2009, Triclinium has collaborated with VPM as the managing CRO for three Phase I and II trials conducted in South Africa with their novel tuberculosis vaccine, VPM1002.
The VPM Days annual meeting brings together a wide group of organisations and academics involved in translation research and development. Triclinium’s Managing Director will present a paper entitled “The regulatory landscape in South Africa and neighbouring countries: updates, challenges and opportunities.” Triclinium has become a regular contributor to this forum. Mr. Strugo was also an invited presenter in 2015 preceded in 2012 by Tracy Southwood, at the time Triclinium’s Project Manager for VPM’s Phase I trial and currently Head of Business Development.
VPM1002 is a recombinant BCG vaccine co-developed by VPM and the Max Planck Society. It was recently out-licensed to Serum Institute of India Ltd, the world’s largest vaccine manufacturer, which will also be represented at the VPM Days this year. The full conference programme is at http://www.vakzine-manager.de